To assess whether resting right ventricular (RV) function assessed by Global RV longitudinal strain (RVLS) and RV fractional area change (FAC) is associated with exercise performance in pulmonary arterial hypertension (PAH) and in chronic thromboembolic pulmonary hypertension (CTEPH). 
Introduction
Pulmonary hypertension (PH) is defined by right heart catheterization (RHC) as increased mean pulmonary arterial pressure (PAP) 25 m mHg at rest. 1 Right ventricular (RV) dysfunction is considered as the major determinant of morbidity and mortality factor in PH. [2] [3] [4] Few papers have looked at the relationship between resting RV function and exercise performance and none has compared this relationship between pre-capillary PH groups. We have previously shown that significant differences in exercise gas exchanges exist between pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). 5 The slope of the ventilation versus carbon dioxide production relationship (VE/VCO 2 ) correlates with 6-min walking distance and discriminates between functional classes in PAH but not in CTEPH. 5 VE/VCO 2 has also been shown to be a good predictor of prognosis in PAH, 5 but this has not been shown in CTEPH. Some trials have shown that when drugs used in PAH (bosentan, sildenafil) are used to treat CTEPH, haemodynamics improve but exercise capacity does not. 6, 7 We hypothesized, therefore, that different factors may play different roles in exercise performance in these two groups. In view of this, we compared the relationship between resting RV function and exercise performance between PAH and CTEPH. Our hypothesis is that the relationship between resting RV function and exercise performance may differ between PAH and in CTEPH.
Methods

Study population
Between November 2013 and July 2014, 120 consecutive patients were prospectively recruited. Criteria for inclusion were pre-capillary PH diagnosed by RHC and sinus rhythm. Furthermore, only patients deemed by the PH team (Hammersmith Hospital, London, UK) to require regular follow-up trans-thoracic echocardiography (TTE) and CPET were invited to participate, and of this cohort, only patients with both procedures performed within a month of each-other with no change in treatment during this time were included.
Patients were categorized into pre-capillary PH groups according to the ESC/ERS guidelines for the treatment and diagnosis of pulmonary hypertension. 1 Pulmonary hypertension was suspected on non-specific symptoms (shortness of breath, fatigue, weakness, angina, dry cough, and syncope) associated with physical signs (left parasternal lift, accentuated second heart sound, pansystolic murmur of tricuspid regurgitation, elevated jugular venous pressure). Patients then had an electrocardiogram, a chest radiograph and TTE. If PH was suspected with TTE (peak tricuspid regurgitation velocity > _2.9 m/s or <2.9 m/s with other PH signs), patients then had pulmonary function tests, ventilation/perfusion lung scan, and high-resolution contrast enhanced computed tomography to identify lung diseases or mismatched perfusion defects. Definite diagnosis was then made with RHC. Pre-capillary PH was defined as mean PAP (mPAP) 25 mmHg and pulmonary wedge pressure (PWP) < _15 mmHg. The classification of PAH and CTEPH were defined in accordance with ESC/ERS guidelines. 1 PAH can be idiopathic, heritable, or drugs and toxins induced. It can also be associated with connective tissue disease, human deficiency virus, portal hypertension, congenital heart disease, and schistosomiasis. Exclusion criteria were incomplete data on echocardiogram (suboptimal imaging), complete bundle branch block (which alters timings of the cardiac cycle), presence of a pacemaker or defibrillator, and groups of pulmonary hypertension other than PAH and CTEPH.
All patients consented to use of their medical data for research purposes; the study was approved by the hospital's ethics committee. The investigation conformed to the principles outlined in the Declaration of Helsinki.
Echocardiographic measurements
A comprehensive TTE was performed by a senior echocardiographer accredited by the British Society of Echocardiography with a Philips (Andover, MA, USA) iE33 probe S5-1 (30 patients), GE (GE Healthcare, Holten, Norway) vivid 7 probe M4S (22 patients), vivid 9 probe M5Sc (22 patients), and Toshiba Artida Aplio (Toshiba Medical Systems Europe BV, Zoetermeer, The Netherlands) probe PST-30B (14 patients). The off-line analysis was performed using a single vendor independent computer analysis system specific for 2D RV Speckle-tracking (Epsilon Imaging/Echo Insight version 2.2.2.837, Michigan, USA) RV systolic function was assessed using Global Right Ventricular Longitudinal Strain (RVLS), therefore including both the RV free wall and the interventricular septum, and RV fractional area change (FAC) RVLS was acquired with images centered on the RV acquired from the apical four chamber view. Images were optimized for speckle-tracking by decreasing the depth to improve spatial resolution, and narrowing the sector width to increase frame rate. Speckle-tracking is a method of measuring myocardial strain defined as the ratio of the change in length over the initial length. In systole, longitudinal strain is negative (myocardium shortens). Speckle-tracking tracks a small area of the myocardium with a unique speckle pattern, coming from scattered ultrasound in the tissue, and measures the deformation of the area. The off-line analysis was performed at the acquisition frame rate. The speckle-tracking was performed by manually tracing the endocardial border of the RV at end diastole. The tracking was then assessed by the software and visually by the reader. Adjustments were made when necessary. FAC was assessed by measuring the RV end diastolic area and end systolic area by endocardial border tracing. RV fractional area change (%) ¼ (end diastolic area -end systolic area)/end diastolic area. (Normal > 35%). 8 The right heart was further assessed according to the American Society of Echocardiography right heart assessment guidelines 8 Tissue Doppler Imaging S' wave was averaged over three cycles.
(Normal > 10 cm/s). 8 Tricuspid Annular Plane Systolic Excursion was measured with the M-mode cursor on the lateral portion of the tricuspid annulus, limiting the sector width to the RV free wall. It is the total excursion of the tricuspid annulus from its highest position after atrial ascent to the peak descent during ventricular systole. It reflects the base-to-apex shortening of the RV in systole (Normal > 16 mm). 8 Right atrial area was measured on 2D greyscale apical four chamber view by tracing the RA wall at end-systole. It was indexed to body surface area calculated by the Mosteller equation from height and weight. RV myocardial performance index was obtained from one cardiac cycle with the tissue Doppler cursor on the RV free wall at the tricuspid annulus. It was taken from an apical four chamber view, with breath held at end expiration. RV myocardial performance index corresponds to (isovolumic contraction time þ isovolumic contraction time)/ejection time (Normal < 0.55). 8 Eccentricity Index was measured on the parasternal short axis at the level of the papillary muscles. It is the ratio of the minor axis of the left ventricle parallel to the septum, divided by the minor axis perpendicular to the septum. It was measured in end-systole and end-diastole Normal values = 1.
8
CPET data collection
CPET was performed on a stationary cycle ergometer according to the recommendations of the American College of Chest Physicians, 9 using a breath-by breath system Master Screen CPX; Jaeger; Hoechberg, Germany). Patients wore a face mask and were supervised by an experienced physiologist and physician. The patients were monitored during a 3-min upright rest period; a 3-min unloaded pedaling period and then during the exercise phase when the work load increased at a rate to achieve a loaded period of 10 min. The exercise continued until the symptom-limited maximum. Arterial blood pressure, 12-lead ECG and peripheral oxygen saturation were continuously recorded. The breathby-breath measurements were ventilation (VE), CO 2 production (VCO 2 ) and VO 2 . PeakVO 2 is the peak oxygen uptake measured during the test divided by the patient's weight and is expressed in mL/min/kg. Maximum workload is the maximum load in watts that the patient reaches. VO 2 max defines the maximal aerobic capacity. Predicted VO 2 max is calculated from the ECSC (European coal and steel community) 1993 formula which includes height, weight, age and gender. VE/VCO 2 slope is an index of ventilatory efficiency. It is the slope measured by the linear regression equation plotting VE against VCO 2 before the respiratory compensation point. It reflects the increase in VE per unit increase of VCO 2 (Normal value < 30). 9 
Statistical analysis
Data were analyzed using IBM SPSS Statistics 21(Chicago, Illinois).
The distribution of the data was assessed by visual review when plotted as a histogram, with normality further confirmed using the ShapiroWilk test. Summary statistics for normally distributed data are given as the mean ± standard deviation, with the median ± interquartile range given for non-parametric data. The unpaired student t test was used to compare normally distributed continuous variables between PAH and CTEPH groups. Non-normally distributed variables were compared with the Mann-Whitney U test. The Chi-squared test was used to assess differences in categorical variables between groups.
As data were not normally distributed, multivariate linear regression analysis was not possible. Spearman correlation was therefore used to assess association between echocardiographic measurements and CPET measurements. All tests were two-tailed and the cut-off for statistical significance was 0.05.
Results
Population
One hundred and twenty patients were prospectively recruited. Thirty-two patients were excluded for inadequate imaging or because they did not qualify for PAH or CTEPH diagnosis ( Figure 1) . Patients' baseline characteristics are presented in Table 1 .
In the PAH group, 6 patients were treated with Sildenafil, 1 with Ambrisentan, 4 with Bosentan, 1 with Diltiazem, 7 with Sildenafil þ Bosentan, 10 with Sildenafil þ Ambrisentan, 1 with Sildenafilþ Treprostinil, 1 with Sildenafil þ Epoprostenol, 1 with Sildenafil þ Epoprostenolþ Bosentan, and 1 with Sildenafilþ Veletri þ Bosentan. Thirteen received no treatment.
In the CTEPH group, 10 patients were treated with Sildenafil, 2 with Ambrisentan, 2 with Bosentan, 1 with Tadalafil, 3 with Bosentanþ Sildenafil, 3 with Ambrisentan þ Sildenafil, and 1 with Sildenafil þ Bosentan þ Veletri. Twenty received no treatment.
In the CTEPH group, there was a higher proportion of men, patients were older and had a higher body mass index than in the PAH group. There were no significant differences in RV function (assessed by RVLS or FAC) nor in exercise performance between groups.
Relation between resting RV function and exercise performance
In the PAH group, resting RV function was correlated with exercise performance. RV function (assessed by RVLS or FAC) was correlated with both percentage predicted VO 2 max and VE/VCO 2 . In the CTPEH group however, no correlation was identified between exercise performance and RV function, whether assessed by RVLS or FAC ( Figure 2) .
Discussion
To the best of our knowledge, this is the first study to compare the relation of resting RV function to exercise performance between PAH and CTEPH. We used two echocardiographic measurements to assess RV function: FAC that has been used for decades, and the relatively recent RVLS. We have shown for the first time that resting RV function is associated with objective measures of exercise performance during cardiopulmonary exercise in PAH but not in CTEPH.
RV function is associated with exercise performance in PAH
We found an association between resting RV function and both CPET measurements that are used in the ESC/ERS guidelines 1 PAH risk assessment strategy: percentage predicted VO 2 max and VE/ VCO 2 . The prognostic importance of resting RV function has long been accepted as a marker of prognosis. 1, 10 It is central to the risk assessment of PAH, guiding treatment decisions. 1 There are few data available in CTEPH. Hardegree and Sachdev showed that RVLS predicted clinical deterioration and mortality in PAH, but they did not study CTEPH. 11, 12 Fine showed that RVLS was a powerful predictor of clinical outcomes in PH, but their cohort was predominantly PAH patients and only 12% included CTEPH patients. Exercise capacity has also been shown to be a powerful marker of prognosis.
14,15 The 6-min walk test has been used as the primary endpoint in many early registration trials for drug therapies for PAH. Recently, Blumberg et al. 16 demonstrated that the change in cardiac output on exercise was the most powerful predictor of survival in PAH and that the typical hemodynamic response to exercise in PH was a pathological increase in PAP and a blunted increase in cardiac output indicating an abnormal pressure/flow relationship. Chaouat et al. 17 and Grunig et al. 18 have both shown that the rise in sPAP on exercise by echocardiography and invasive haemodynamics, respectively, is predictive of survival in PAH. In addition, the change in the exercise cardiac index with therapy showed a good correlation with change in exercise capacity. Our data confirm an association in the PAH population between RV function as assessed by RVLS and FAC with exercise performance.
In PAH, we also found an association between RV function and VE/VCO 2 . VE/VCO 2 reflects ventilatory efficiency which is the ability of the lung to clear CO 2 . VE/VCO 2 increases in PH because of hyperventilation due to heart failure which leads to a low partial arterial carbon dioxide pressure. 6 There is also a contribution from increased ventilatory dead space fraction due to ventilation-perfusion mismatch which reflects the extent of pulmonary vascular disease. VE/VCO 2 is effort and motivation independent and is related to symptoms. 15 It is an objective reproducible measurement of cardio-pulmonary performance. As with RVLS or FAC, there is no modification for age, gender, height, or weight. Previous studies have found VE/VCO 2 to be better related to clinical outcomes than other CPET parameters.VE/VCO 2 can be obtained even if the patient does not reach his VO 2 max and is of higher prognostic value than VO 2 max in patients with heart failure. 19 Schwaiblmair et al. 15 showed that Right ventricular function in PAH not in CTEPH VE/VCO 2 was the best CPET predictor of mortality in PH patients, while Deboeck et al. 14 showed that VE/VCO 2 < 54 was an independent predictor of survival in PAH. The association we found between VE/VCO 2 and RV function supports the role of VE/VCO 2 as a marker of right ventricular failure in PAH. Precise parameters to assess PAH severity still need to be determined. Among the parameters currently used in risk assessment/determinants of prognosis in the ESC/ERS PH guidelines, 1 there are many drawbacks. The WHO-FC has great inter-observer variability. The 6MWT is influenced by weight gender, motivation, height, and age. CPET is contra-indicated if syncope or acute right-sided heart failure, RHC is invasive, BNP/NTproBNP have high variability and are not PH specific. On the other hand, RVLS assessed by 2D speckletracking can quantify small variations, is reproducible, independent of patient motivation and can be analyzed at the bed-side in severely diseased patients. RVLS is related to percentage predicted VO 2 max and VE/VCO 2 , which in turn is linked prognosis. Consequently, it could make a significant contribution to non-invasive assessment of PAH patients. In PAH, ESC/ERS guidelines 1 recommend TTE and CPET be performed at baseline, every 6-12 months, 3-6 months after changes in therapy and in case of clinical worsening. As we have shown that RV function is correlated to exercise performance and that RVLS is reliable and reproducible, it might be possible to space out exercise testing in PAH patients.
There is no association between resting RV function and exercise performance in CTEPH
Given that most data [11] [12] [13] [14] [15] [16] analyzing the relation between RV function, exercise capacity, and prognosis arise from studies of PAH, there is clearly a need to understand the relationship between RV function and exercise capacity in CTEPH, to determine if changes in exercise capacity reflect changes in RV function which remains likely to be the most important determinant of outcome. Our data does not support this, as we have shown that, in CTEPH, changes in exercise capacity are not reflected by changes in RV function. We have previously shown that excess dead space ventilation in CTEPH (due proximal vascular occlusion) may explain a disconnection between exercise performance, specifically ventilatory efficiency (VE/VCO 2 ) and disease severity, and therefore RV function. 5 This study provides further support that exercise capacity may not reflect RV function or even underlying severity of CTEPH as faithfully as it does in PAH. In the past, clinical trials have shown that when the PAH therapies bosentan and sildenafil 6, 7 have been trialed in CTEPH, haemodynamics have improved, but exercise capacity has not. One explanation we have proposed is that this relates to this apparent disconnection between gas exchange and disease severity. Unlike in PAH, where ESC/ERS guidelines 1 have defined a precise risk assessment strategy and determinants of prognosis, with followup exams and timing there are no such recommendations in CTEPH. This confirms the gaps in evidence for markers of prognosis in CTEPH and the need for further studies. Our study shows that there are major differences between PAH and CTEPH, that CPET may not be accurate in risk assessment in CTEPH. Follow-up and risk assessment should be thoroughly different in these groups.
Study limitations
The study was single-center and would need to be replicated in other centers. We were not able to assess the relationship of RV function to 6-min walk distance since we do not undertake CPET and walk testing on the same day.
There was a significant difference in age between groups and we were not able to adjust for age with multivariate regression because of the non-normal distribution of data. However, we overcame this issue by analyzing percentage of predicted VO 2 max which is already adjusted to age, height, weight and gender and VE/VCO 2 which is barely influenced by height, weight, age, gender, and locomotor comorbidities. Furthermore, VE/VCO 2 and percentage of predicted VO 2 max are the two CPET measurements that are used in risk assessment/determinants of prognosis in the ESC/ERS PH guidelines. 1 Finally, by including PAH and CTEPH only, and excluding other causes of PH, we also excluded patients with significant other cardiac and pulmonary conditions.
In the CTEPH group was relatively heterogeneous within the overall umbrella diagnosis of CTEPH: 12 patients were pre-pulmonary endarterectomy (PEA), 6 had distal or inoperable CTEPH, 5 patients had refused PEA, and 18 had persistent PH post-PEA. Although these subgroups could behave differently, none of our subgroup analyses suggest so: there was no relation between resting RV function and exercise performance in any CTEPH subgroup. The data on the CTEPH subgroup excluding post PEA patients can be found in the supplementary tables (Appendices). It was important to check that this subgroup in particular did not behave differently because it has been shown that RV free wall longitudinal contraction is impaired after surgery with pericardiotomy. 20 We chose to present the results analyzing Global RVLS, including the interventricular septum and therefore also left ventricular components. This is because, although the correlation remained significant analyzing free-wall RVLS only, the correlation was stronger using global RVLS. Data analyzing free-wall RVLS are available upon request.
We did not assess RV function on exercise to determine whether relationships were maintained on exercise or unmasked. This is because we decided to look at a tool that can be easily and repeatedly used in a clinical setting. It is particularly interesting to have shown this relation at rest, because resting RV function can be easily assessed rapidly at the bedside in severely diseased patients whereas exercise testing implies more time, equipment and staff. Our findings are consistent with those of Claessen et al. 21 who showed that in CTEPH resting measures of RV function did not explain variance of exercise capacity, however exercise measures did. It is however, striking that resting measurements do correlate to exercise capacity in PAH. This implies different adaption mechanisms to exercise between groups. Although only one post-acquisition analysis software was used, the images were acquired with three brands of echocardiographs. To ensure this caused no bias, we analyzed inter-echocardiograph brand reproducibility with Bland-Altman plots: 10 normal adults were scanned by the same operator with all three brands of echocardiographs on the same day (Table 2, Figure 3 
Conclusion
In PAH, resting RV function as assessed by FAC and RVLS is closely related to exercise performance. RVLS could therefore make a significant contribution to non-invasive assessment of PAH patients. On the other hand, resting RV function is not associated with exercise performance in CTEPH. This implies that resting RV function and exercise performance may be less closely associated in CTEPH and other factors such as ventilation-perfusion mismatch may play a role. The role of exercise performance as prognostic maker in CTEPH remains uncertain.
Supplementary data
Supplementary data are available at European Heart Journal -Cardiovascular Imaging online. 
